Register for our free email digests:

Arteaus Therapeutics takes on Lilly’s migraine compound; Lilly later regains rights
Executive Summary
Specialty pharma start-up Arteaus Therapeutics LLC has licensed worldwide rights to develop one of Eli Lilly & Co.’s early-stage migraine prevention compounds.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Concluded
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
- Reverse Licensing
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com